ECMO/ECLS: systemic inflammation and interference of homeostasis in patients with extracorporeal heart-/lungsupport

• Conditions: patients with acute heart- and/or lung failure; R57.0; J80; R65; Cardiogenic shock; Adult respiratory distress syndrome; Systemic Inflammatory Response Syndrome [SIRS]

• Registration Number: DRKS00011106
• Lead Sponsor: niversitätsherzzentrum Freiburg - Bad KrozingenAbteilung Kardiologie und Angiologie I

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Study Start: 2016-09-22
• Results First Posted: 2020-11-09
• Study Completion: 2023-01-31
• Last Update Posted: 19 August 2024

Recruitment & Eligibility

• Status: Complete
• Sex: All
• Target Recruitment: 89

Inclusion Criteria

patients with ECMO/ECLS

Exclusion Criteria

hemato-oncological basic disease;
severe anemia requiring transfusions (Hb < 7 g/dl)

Study & Design

• Study Type: observational
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
detection of changes in hemostasis and vascular inflammation using blood test (standardized laboratory methods and specialized analytical methods (e.g. FACS, PCR, protein analysis) in the laboratory of the study coordinator)) before, during and after ECMO/ECLS support

Secondary Outcome Measures

Name	Time	Method
correlation of criteria 1) with survival